Patient 1: 53-Year-Old Man With CVD Risk Factors

Slides:



Advertisements
Similar presentations
Lipoprotein Management. Step 1: Assess clinical CHD risk (Very-High, High, Moderately-High, Moderate, Low Risk) Step 2: Establish goals of therapy appropriate.
Advertisements

Residual CVD Risk Niacin and Simvastatin P. Pauletto Medicina Interna I^, Treviso University of Padova - Italy.
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
The Latest Lipid Guidelines:
Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Monitoring and Modifying Treatment in PAH
Statin Selection in the Elderly
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
An Endocrinology Clinic in Dyslipidemia
Omega-3 Prescriptions vs Supplements in Practice
Tailoring Statin Therapy in Women
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Back to the Basics of Dyslipidemia
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patients aged 85yrs and over
Select Topics in Cardiovascular Medicine
Obesity and Dyslipidemia: How Would You Treat?
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Antiplatelet Therapy and Secondary Prevention
An Update on PCSK9 Inhibitors
Best Practices in Metastatic Colorectal Cancer
Evaluating LDL-C Recommendations
What's New in Dyslipidemia?
62-year-old Man With Unstable Angina
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
CV Risk Doesn't End in the Cath Lab
Personalizing Statin Therapy in Patients With HIV
PCSK9 Inhibitors and Cardiovascular Outcomes
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Risk Stratification in CAD and PAD
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
New LDL-C Lipid Targets
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
CV Risk Doesn't End in the Cath Lab
Management of Systematic Lupus Erythematosus
Clinicians' Corner in Dyslipidemia
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Clinical Issues in AIP:
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Statins, Obesity, and Hyperlipidemia
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Lipid Updates From Spring 2019
An Update on PCSK9 Inhibitors
PCSK9 Inhibitors and Statin Intolerance
PAH Pathways: What Do the Data Tell Us?”
Updates on Dyslipidemia
Dyslipidemia And Diabetes
PCSK9 Inhibitors and Real-World Evidence
Section 6: Update on lipid treatment guidelines
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Clinical Cases of Mixed Dyslipidemia: Perspectives From a Community Cardiologist

Patient 1: 53-Year-Old Man With CVD Risk Factors

Patient 1: Physical Examination Findings

Patient 1: Laboratory Results

Patient 1: Very High Risk for CVD and MI

Steno-2: Benefit of Targeted, Intensified, Multifactorial Intervention of Modifiable Risk Factors for CVD

Patient 1: Risk Factor Modification Goals

Statin Treatment: Primary Treatment for Secondary Prevention of CVD

Therapeutic Options After Maximizing Statin Therapy: Niacin

Therapeutic Options After Maximizing Statin Therapy: Ezetimibe

Therapeutic Options After Maximizing Statin Therapy: Bile Acid Resins

Therapeutic Options After Maximizing Statin Therapy: Fibrates

Patient 2: 64-Year-Old Woman With Complaints of Muscle Pain

Patient 2: Physical Examination Findings

Patient 2: Laboratory Results

Approach to Statin Intolerance

Abbreviations

References

References (cont)